Citation Impact
58 standout
Citing Papers
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
2024 Standout
Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer
2024 Standout
Works of Jochem Potenberg being referenced
Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: Final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.
2022
Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.
2021
Author Peers
| Author | Oncology | Cancer Research | PRM | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|
| Jochem Potenberg | 223 | 150 | 95 | 32 | 310 | |
| Geir Niemi | 10 | 11 | 17 | 558 | ||
| Ayşe Durnalı | 149 | 89 | 144 | 24 | 309 | |
| Romy Fröhlich | 29 | 274 | ||||
| Toshikazu Kawagoe | 1 | 9 | 30 | 449 | ||
| Cécile Mouly | 11 | 79 |
All Works
Login with ORCID to disown or claim papers
Loading papers...